All In Biotech

Drug Trial Radar · NCT07764861

A Open-Label Phase in Participants With Multiple Myeloma

A Multi-Center, Open-Label Phase II Study of IBI3003 in Combination With Anti-CD38 Monoclonal Antibody in Participants With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 15, 2026

Primary completion

Dec 31, 2026

Study completion Jun 30, 2031

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma. This study includes a safety run-in period and 2 cohorts (Cohorts 1 and 2).In the safety run-in period, subjects with measurable relapsed or refractory multiple myeloma who had previously received at least 1 line of systemic anti-myeloma therapy and had a history of dual drug exposure (at least one proteasome inhibitor and one immunomodulatory agent) were enrolled, mainly to evaluate the safety and tolerability of IBI3003 in combination with anti-CD38 monoclonal antibody and to determine the recommended phase 2 dose of IBI3003 in combination with anti-CD38 monoclonal antibody.Cohort 1 mainly enrolls newly diagnosed MM(Multiple myeloma)patients who are ineligible for or refusing ASCT(Autologous Stem Cell Transplantation), and Cohort 2 enrolls newly diagnosed MM patients who are eligible for and willing to undergo ASCT. The 24-week MRD negative rate of IBI3003 in combination with anti-CD38 monoclonal antibody in the participant population is mainly evaluated.

Conditions

  • Multiple Myeloma

Interventions

  • DexamethasoneDrug

    A potent synthetic glucocorticoid

  • IBI3003Biological

    Recombinant humanized anti-GPRC5D/BCMA/CD3 trispecific antibody injection

  • LenalidomideDrug

    An Oral Immunomodulator And Antineoplastic Drug

  • DaratumumabDrug

    Anti-cancer monoclonal antibody targeting CD38

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRD( Minimal Residue Disease) negativity rate at 24 weeksTime frame: 24weeks
  2. AE(Adverse event)Time frame: 30Days
  3. TEAE(Treatment emergent adverse event)Time frame: 30Days
  4. SAE(Serious Adverse Event)Time frame: 30Days
  5. AESI( Adverse event of special interest)Time frame: 30Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.